Takeda’s zasocitinib has shown strong rates of skin clearance, as well as other benefits, in new study results regarding ...

Oregon Medical Research Center in Portland, Oregon, has led a phase 2 trial in moderate-to-severe plaque psoriasis that ...

In both trials, envudeucitinib showed greater skin clearance than placebo on both co-primary endpoints at week 16.

CNW/ - Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited ("Sun Pharma"), is pleased ...

Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque ...

ATLANTA, Sept. 17, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced three- and four-year data from across the open-label extension (OLE) Phase 3 trials for BIMZELX® ...

Alumis (ALMS) shares climbed nearly 150% on Tuesday after the autoimmune disease drug developer said its lead candidate, ...

THOUSAND OAKS, Calif., Aug. 20, 2024 /PRNewswire/ -- Amgen (AMGN) today announced Otezla ® (apremilast) is now available in the U.S. for pediatric use. Earlier this year, the U.S. Food and Drug ...

Alumis Inc. surged on Phase 3 psoriasis data for envudeucitinib. Click for this look at ALMS stock and why I am bullish on ...

Otezla is the first oral therapy approved for moderate to severe plaque psoriasis in this patient population. The Food and Drug Administration (FDA) has expanded the approval of Otezla ® (apremilast) ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. PASI 75 responses among patients treated with AX-158 ...